Kinetics of viral load and antibody response in relation to COVID-19 severity

Wang，Yanqun1; Zhang，Lu2; Sang，Ling1; Ye，Feng1; Ruan，Shicong3; Zhong，Bei4; Song，Tie5; Alshukairi，Abeer N.6; Chen，Rongchang7; Zhang，Zhaoyong1; Gan，Mian1; Zhu，Airu1; Huang，Yongbo1; Luo，Ling1; Mok，Chris Ka Pun8; Al Gethamy，Manal M.9; Tan，Haitao3; Li，Zhengtu1; Huang，Xiaofang1; Li，Fang1; Sun，Jing1; Zhang，Yanjun1; Wen，Liyan1; Li，Yuming1; Chen，Zhao1; Zhuang，Zhen1; Zhuo，Jianfen1; Chen，Chunke1; Kuang，Lijun1; Wang，Junxiang1; Lv，Huibin8; Jiang，Yongliang4; Li，Min4; Lin，Yimin4; Deng，Ying4; Tang，Lan4; Liang，Jieling4; Huang，Jicheng10; Perlman，Stanley11; Zhong，Nanshan1; Zhao，Jingxian1; Malik Peiris，J. S.8; Li，Yimin1; Zhao，Jincun1,2

2020-10-01

10.1172/JCI138759

JOURNAL OF CLINICAL INVESTIGATION   影响因子和分区

0021-9738

1558-8238

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for coronavirus 2019 (COVID-19) pneumonia. Little is known about the kinetics, tissue distribution, cross-reactivity, and neutralization antibody response in patients with COVID-19. Two groups of patients with RT-PCR-confirmed COVID-19 were enrolled in this study: 12 severely ill patients in intensive care units who needed mechanical ventilation and 11 mildly ill patients in isolation wards. Serial clinical samples were collected for laboratory detection. Results showed that most of the severely ill patients had viral shedding in a variety of tissues for 20-40 days after onset of disease (8/12, 66.7%), while the majority of mildly ill patients had viral shedding restricted to the respiratory tract and had no detectable virus RNA 10 days after onset (9/11, 81.8%). Mildly ill patients showed significantly lower IgM response compared with that of the severe group. IgG responses were detected in most patients in both the severe and mild groups at 9 days after onset, and remained at a high level throughout the study. Antibodies cross-reactive to SARS-CoV and SARS-CoV-2 were detected in patients with COVID-19 but not in patients with MERS. High levels of neutralizing antibodies were induced after about 10 days after onset in both severely and mildly ill patients which were higher in the severe group. SARS-CoV-2 pseudotype neutralization test and focus reduction neutralization test with authentic virus showed consistent results. Sera from patients with COVID-19 inhibited SARS-CoV-2 entry. Sera from convalescent patients with SARS or Middle East respiratory syndrome (MERS) did not. Anti-SARS-CoV-2 S and N IgG levels exhibited a moderate correlation with neutralization titers in patients' plasma. This study improves our understanding of immune response in humans after SARS-CoV-2 infection.

SCI

英语

NI期刊 ; ESI高被引

其他

National Key Research and Development Program of China[2018YFC1200100][2018ZX10301403] ; emergency grants for prevention and control of SARS-CoV-2 from the Ministry of Science and Technology[2020YFC0841400] ; Guangdong province[2020B111108001][2018B020207013][2020B111112003] ; Guangdong Province Basic and Applied Basic Research Fund[2020A1515010911] ; National Key Technology RD Program[2018YFC1311900] ; Guangdong Science and Technology Foundation[2019B030316028] ; State Key Laboratory of Respiratory Disease[SKLRD-QN-201715][SKLRD-QN-201912][SKLRD-Z-202007] ; Guangzhou Medical University[159] ; NIH[P01 060699] ; National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme[N_HKU737/18] ; Research Grants Council of the Hong Kong Special Administrative Region, China[T11-712/19-N]

Research & Experimental Medicine

Medicine, Research & Experimental

WOS:000582387500028

AMER SOC CLINICAL INVESTIGATION INC

CLINICAL MEDICINE

2-s2.0-85092219443

Scopus

1.State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,First Affiliated Hospital,Guangzhou Medical University,Guangzhou, Guangdong,China
2.Institute of Infectious Disease,Guangzhou Eighth People's Hospital,Guangzhou Medical University,Guangzhou, Guangdong,China
3.Yangjiang People's Hospital,Yangjiang, Guangdong,China
4.Sixth Affiliated Hospital,Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan, Guangdong,China
5.Guangdong Provincial Center for Disease Control and Prevention,Guangzhou, Guangdong,China
6.King Faisal Specialist Hospital and Research Centre,Jeddah,Saudi Arabia
7.Shenzhen Institute of Respiratory Disease,First Affiliated Hospital (Shenzhen People's Hospital),South University of Science and Technology of China,Shenzhen, Guangdong,China
8.HKU-Pasteur Research Pole,School of Public Health,Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
9.Al Nour Specialist Hospital,Makkah,Saudi Arabia
10.Technology Centre,Guangzhou Customs,Guangzhou, Guangdong,China
11.Department of Microbiology and Immunology,University of Iowa,Iowa City,United States

Wang，Yanqun,Zhang，Lu,Sang，Ling,et al. Kinetics of viral load and antibody response in relation to COVID-19 severity[J]. JOURNAL OF CLINICAL INVESTIGATION,2020,130(10):5235-5244.

Wang，Yanqun.,Zhang，Lu.,Sang，Ling.,Ye，Feng.,Ruan，Shicong.,...&Zhao，Jincun.(2020).Kinetics of viral load and antibody response in relation to COVID-19 severity.JOURNAL OF CLINICAL INVESTIGATION,130(10),5235-5244.

Wang，Yanqun,et al."Kinetics of viral load and antibody response in relation to COVID-19 severity".JOURNAL OF CLINICAL INVESTIGATION 130.10(2020):5235-5244.